BioSpace News Archive

Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the fifth dose escalation cohort in the ALS-6000-101 dose escalation Phase 1 clinical trial to evaluate the safety and tolerability of AVA6000 has been completed successfully.

SCYNEXIS, Inc. today announced the achievement of a $25 million performance-based development milestone under its exclusive license agreement with GSK for ibrexafungerp.

UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the design of its Phase 2b ASPIRE clinical trial, which will evaluate UBX1325 (foselutoclax) head-to-head against aflibercept in previously treated patients with active diabetic macular edema (DME) who are not achieving optimal benefit from standard of care.

23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ subscription service on the genetics of panic attacks, or episodes of intense anxiety with symptoms that include hyperventilation and a racing heart.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced promising interim data, including up to 24 months of follow-up, from 26 patients enrolled in the ongoing U.S. Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.

Noema Pharma today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company.

PTC Therapeutics, Inc. today shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in Huntington’s disease (HD) patients.

bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel) for priority review.

ADAMA Ltd. announces the registration of Sierra®, its self-produced Saflufenacil-based herbicide formulation, the first off-patent product based on this active ingredient, in Australia.

Pieris Pharmaceuticals, Inc. announced that partner AstraZeneca yesterday communicated to Pieris its decision to discontinue and cease dosing in the ongoing clinical studies of elarekibep.